Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut (CDX-110)
|ClinicalTrials.gov Identifier: NCT03068650|
Recruitment Status : No longer available
First Posted : March 3, 2017
Last Update Posted : October 18, 2017
Information provided by (Responsible Party):
Celldex endeavors to make investigational products available to patients with life-threatening diseases who have exhausted other treatment options and where there is a reasonable expectation of benefit over risk. Requests for expanded access to rindopepimut in patients with EGFRvlll expressing recurrent glioblastoma will be considered.
|Condition or disease||Intervention/treatment|
|Recurrent GBM||Biological: rindopepimut|
|Study Type :||
|Official Title:||Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut (CDX-110)|
Rindopepimut is an experimental cancer vaccine that may act to promote anti-cancer effects in patients who have glioblastoma multiforme (GBM) that expresses an EGFR mutation, called EGFRvIII. Data from, a randomized, controlled phase 2 study in patients with EGFRvIII positive progressive glioblastoma (the ReACT trial) suggested that vaccination with rindopepimut could improve survival. A randomized, controlled phase III study in patients with newly diagnosed EGFRvIII expressing GBM did not show a survival advantage from rindopepimut vaccination.
No Contacts or Locations Provided